Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy
TLR4 agonists have been proposed as immunotherapeutics in cancer. Here, the authors show the TLR4-dependent adjuvant effect of FimH, an E. coli adhesin, in promoting dendritic cell mediated-T cell activation and response to immune checkpoint blockade in preclinical cancer models.
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2020-03-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-020-15030-4 |